30 results about "Stem cell homing" patented technology

Bioscaffoldings formed of hydrogels that are crosslinked in situ in an infarcted region of the heart (myocardium) by a Michael's addition reaction or by a disulfide bond formed by an oxidative process are described. Each of the bioscaffoldings described includes hyaluronan as one of the hydrogel components and the other component is selected from collagen, collagen-laminin, poly-l-lysine, and fibrin. The bioscaffolding may further include an alginate component. The bioscaffoldings may have biofunctional groups such as angiogenic factors and stem cell homing factors bound to the collagen, collagen-laminin, poly-l-lysine, or fibrinogen hydrogel component. In particular, the biofunctional groups may be PR11, PR39, VEGF, bFGF, a polyarginine/DNA plasmid complex, or a DNA/polyethyleneimine (PEI) complex. Additionally, the hydrogel components may be injected into the infarct region along with stem cells and microspheres containing stem cell homing factors. The bioscaffolding may be formed on a stent or a cardiac medical device.

A composition having a bispecific antibody which binds a stem cell specific antigen and a tissue, differentiated cell or condition associated antigen and an agent that enhances expression of the tissue, differentiated cell or condition associated antigen, is provided. Also provided are methods of using the bispecific antibodies and/or agents to enhance cell therapy.

Bioscaffoldings formed of hydrogels that are crosslinked in situ in an infarcted region of the heart (myocardium) by a Michael's addition reaction or by a disulfide bond formed by an oxidative process are described. Each of the bioscaffoldings described includes hyaluronan as one of the hydrogel components and the other component is selected from collagen, collagen-laminin, poly-1-lysine, and fibrin. The bioscaffolding may further include an alginate component. The bioscaffoldings may have biofunctional groups such as angiogenic factors and stem cell homing factors bound to the collagen, collagen-laminin, poly-1-lysine, or fibrinogen hydrogel component. In particular, the biofunctional groups may be PR11, PR39, VEGF, bFGF, a polyarginine/DNA plasmid complex, or a DNA/polyethyleneimine (PEI) complex. Additionally, the hydrogel components may be injected into the infarct region along with stem cells and microspheres containing stem cell homing factors. The bioscaffolding may be formed on a stent or a cardiac medical device.

A method of enhancing cell engraftment potential is provided. The method comprising ex-vivo or in-vitro subjecting a population of cells to an amount of nicotinamide for a period of time sufficient to effect the population of cells, thereby enhancing cell engraftment potential.

Chemokines ligands to at least one of CCR1, CCR2, CCR3, or CCR5 can be used to home stem cells for therapeutic applications.

The present invention relates to the fields of hematopoietic stem cell transplantation and molecular biology. More specifically, methods for improving engraftment efficiency in stem cell transplants by improving stem cell homing to bone marrow are provided.

The invention provides a method which enables stem cells to be homed quickly and effectively. The stem cell homing method includes the steps that immunomagnetic beads are used for marking the stem cells, and the particle size of each immunomagnetic bead is 40-60 nanometers; the marked stem cells are injected into a circulatory system of specific tissue; and a positive magnetic pole and a negative magnetic pole point to body surface portions corresponding to the specific tissue, and in the circulation process of the circulatory system, the stem cells are homed into the specific tissue quickly and accurately, wherein the magnetic field strength between the positive magnetic pole and the negative magnetic pole is 8,400-18,600 gausses. According to the stem cell homing method, the magnetic characteristic of the superparamagnetism magnetic beads is utilized innovatively, the magnetic attraction technology is adopted to enable the stem cells to be homed into the specific tissue, the stem cells can be helped to differentiate into functional adult cells in the specific tissue, and a new direction is exploited for clinical application of the stem cells.

The invention relates to the field of articular cartilage injury repair and particularly relates to an adipose-derived stem cell transfected by a magnetic nanoparticle mediated IGF-I gene and a preparation method thereof. The method comprises three steps of ADSCs separation and culture, Fe3O4 MNPs preparation and in vitro transfection. The mediated IGF-I gene with an iron oxide magnetic nanoparticle as a vector is used for transfecting ADSCs to achieve over expression of IGF-I, and the homing rate of stem cells is improved by a dynamically rotating magnetic field in vitro in a targeting manner, and the iron oxide magnetic nanoparticle used in the research is a non-virus gene vector, has the advantages of being safe, harmless, high targeting and efficient and stable expression of a target gene, and the like, can be used for greatly improving the gene transfection efficiency, and more importantly can be used for solving the problem of low homing rate of ADSCs in a scaffold in an implant via the dynamically rotating magnetic field in vitro, and positioning and tracking the stem cell in vivo through magnetic resonance technology.

The present invention provides a channel ushering drug common achyranthes-containing traditional Chinese drug composition for improving bone marrow stem cell homing. The traditional Chinese drug composition is prepared from the following raw material drugs, wherein the raw material drugs comprise, by weight, 10-20 parts of common achyranthes, 15-45 parts of mongolian milkvetch root, 10-20 parts of angelica, 10-20 parts of szechwan lovage rhizome, 6-18 parts of red peony root, 10-20 parts of peach seed, 10-20 parts of safflower, 10-20 parts of lumbricus, 10-20 parts of cassiabarktree twig, 10-20 parts of common floweringquine fruit, and 10-20 parts of clematis chinensis osbeck. According to the present invention, the channel ushering drug common achyranthes-containing traditional Chinese drug composition of the present invention has the effect of improvement of autologous bone marrow stem cell homing so as to improve bone repair and vascular regeneration inside the femur head, and provides significant effects for delaying of disease developments of femur head necrosis and other osteoarticular diseases. In addition, the traditional Chinese drug composition has characteristics of lowtoxic and side-effects and low price.

The invention relates to the technical field of biology, in particular to a recombinant vector and a stable cell strain containing the recombinant vector. The recombinant vector and the stable cell strain containing the recombinant vector can be used for screening stem cell homing promotion drugs. The recombinant vector contains a CXCR4 promoter sequence and a luc2 luciferase report gene; and theluc2 luciferase report gene is positioned at the downstream of the CXCR4 promoter sequence. The stable cell strain which contains the recombinant vector and an internal reference luciferase vector canbe used for detecting the expression activity level of the CXCR4 gene, and then are used for screening the stem cell homing promotion drugs at high throughput. Therefore, the stable cell strain is added in a candidate drug for stimulation, through luc2 relative fluorescence intensity, the activity of promotion of the candidate drug on expression of the CXCR4 promoter can be evaluated, therefore,the stem cell homing drugs or drugs for treating myocardial infarction or assisting in treatment of the myocardial infarction are screened, and the application prospect is wide.

The invention relates to the field of medicine, and in particular relates to a fusion polypeptide, an application of the fusion polypeptide in enhancement of stem cell homing ability and anti-apoptotic ability and a pharmaceutical composition. The fusion polypeptide includes an SDF-1 derived peptide, an optional linker sequence and an RGD peptide having an RGD sequence in sequence from the 5' endto the 3' end, wherein the linker sequence is used to link the SDF-1 derived peptide and the RGD peptide, the SDF-1 derived peptide can specifically bind to CXCR4 and/or CXCR7 receptors expressed by stem cells, and the RGD peptide can specifically bind to an integrin receptor. The fusion polypeptide has the advantages of low costs and a long half-life period, and can enhance the homing ability andanti-apoptotic ability of the stem cells.

The present invention provides methods for increasing engraftment of stem cells in a subject by treating the cells with a Gαs activator. The invention further provides methods for identifying Gαs activators for use in increasing engraftment of stem cells in a subject.

The invention relates to a bioactive scaffold for repairing endometrium and improving fertility. The scaffold comprises a substrate and bioactive factors contained by the substrate. Endogenous stem cells are recruited and captured by bioactive factors. The stem cells have pluripotency and play a role in immune regulation and control on a wound surface, thereby effectively promoting endometrial repairing and remarkably increasing the fertility rate. According to the invention, the endogenous stem cell homing means integrated with collection and capturing is employed to repair the damaged endometrium so as to solve problems of intrauterine adhesion, reduced fertility rate and the like caused by a hysteroscope operation, thereby eliminating the potential safety hazards caused by usage of exogenous cells in the traditional repair material. The adopted raw materials have high biocompatibility; the preparation process is simple; exogenous cells are not contained; and the biological safety ishigh.

The present invention discloses a method of treating the infarcted myocardial tissue, including the concentration of SDF-1 protein in the infarcted tissue. The concentration of stem cells in the peripheral blood of the infarcted tissue is also increased. When the concentration of SDF-1 protein in the infarcted tissue is increased, the number of stem cells in the peripheral blood is also increased at the same time.

The present invention relates to a cell-free, multi-layered medical device having bespoke, multifunctional bioactivity for the purpose of regeneration of skeletal tissues. The medical device may actively promote homing of stem cells into the medical device and promote their differentiation into the required cell type and promote de-novo tissue formation. The invention includes methods of making the medical device, uses of the medical device in promoting regeneration of the articular cartilage of a joint surface and in promoting healing and regeneration of skeletal tissues, for example, meniscal cartilage, tendon and ligament tissues and also healing of bone tissue indications such as fractures.

The invention discloses the human chemokine HCC-1, N-terminally truncated HCC-1 molecules and glycosylated HCC-1 which improve the homing of stem cells into the -bone marrow during stem cell transplantation. It is also provided a procedure for producing the polypeptides by recombinant techniques or chemical synthesis and for producing antibodies against such polypeptide. Furthermore, it is disclosed the modification of the polypeptide by coupling of amino acid residues and/or chemical groups or deleting amino-acids generating potent derivatives of the polypeptide. Another aspect of the invention provides a combination of the polypeptide of the present invention and a suitable pharmaceutical carrier for providing a therapeutically effective amount of the polypeptide for the treatment of various associated diseases. The invention concerns also the use of the HCC-1 molecules to increase engraftment of stem cells in the course of the stem cell transplantation performed in stem cell transplantation related diseases.

Intracoronary delivery of endothelial progenitor cells (EPCs) is an emerging concept for the treatment of cardiovascular disease, and enhancement of EPC adhesion to vascular endothelium should improve cell retention within targeted organs, as well as vascular development. The present inventors have shown that stimulation of adenosine receptors (AdoR) in murine embryonic EPCs (eEPCs) and cardiac endothelial cells (cECs) rapidly, within minutes, increased eEPC adhesion to cECs. eEPCs and cECs were found to predominantly express functional A₁ and A_2B AdoR subtypes, respectively, and both subtypes are involved in the regulation of eEPC adhesion to cECs. Adenosine, adenosine precursors (e.g., AMP) and adenosine receptor agonists thus can be used to stimulate EPC/stem cell homing and engraftment in cell-based therapies.